Design, synthesis and biological evaluation of a 4,6-di(aziridin-1-yl)-1,3,5-triazine–benzimidazole hybrid as a potential dual-targeting anticancer agent

Ivan S. Chernov, Alexandra V. Protas, Elena А. Popova, Olga S. Shemchuk, Natalia V. Petukhova, Gulalek Babayeva, Valeria M. Tretiakova, Vyacheslav E. Bulakov, Pavel K. Kozhukhov, Olga V. Mikolaichuk, Il’ya V. Kornyakov, Vadim S. Pokrovsky, Konstantin N. Semenov, Vladimir V. Sharoyko

Open source

DOI: 10.1080/17568919.2026.2658014
Published: 2026-04-22
Container: Future Medicinal Chemistry
Publisher: Informa UK Limited
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1080/17568919.2026.2658014,
  title = {Design, synthesis and biological evaluation of a 4,6-di(aziridin-1-yl)-1,3,5-triazine–benzimidazole hybrid as a potential dual-targeting anticancer agent},
  author = {Ivan S. Chernov and Alexandra V. Protas and Elena А. Popova and Olga S. Shemchuk and Natalia V. Petukhova and Gulalek Babayeva and Valeria M. Tretiakova and Vyacheslav E. Bulakov and Pavel K. Kozhukhov and Olga V. Mikolaichuk and Il’ya V. Kornyakov and Vadim S. Pokrovsky and Konstantin N. Semenov and Vladimir V. Sharoyko},
  year = {2026},
  journal = {Future Medicinal Chemistry},
  doi = {10.1080/17568919.2026.2658014},
  url = {https://doi.org/10.1080/17568919.2026.2658014}
}

RIS

TY  - JOUR
TI  - Design, synthesis and biological evaluation of a 4,6-di(aziridin-1-yl)-1,3,5-triazine–benzimidazole hybrid as a potential dual-targeting anticancer agent
AU  - Ivan S. Chernov
AU  - Alexandra V. Protas
AU  - Elena А. Popova
AU  - Olga S. Shemchuk
AU  - Natalia V. Petukhova
AU  - Gulalek Babayeva
AU  - Valeria M. Tretiakova
AU  - Vyacheslav E. Bulakov
AU  - Pavel K. Kozhukhov
AU  - Olga V. Mikolaichuk
AU  - Il’ya V. Kornyakov
AU  - Vadim S. Pokrovsky
AU  - Konstantin N. Semenov
AU  - Vladimir V. Sharoyko
PY  - 2026
JO  - Future Medicinal Chemistry
DO  - 10.1080/17568919.2026.2658014
UR  - https://doi.org/10.1080/17568919.2026.2658014
ER  -

APA

Chernov, I. S., Protas, A. V., Popova, E. А., Shemchuk, O. S., Petukhova, N. V., Babayeva, G., Tretiakova, V. M., Bulakov, V. E., Kozhukhov, P. K., Mikolaichuk, O. V., Kornyakov, I. V., Pokrovsky, V. S., Semenov, K. N., & Sharoyko, V. V. (2026). Design, synthesis and biological evaluation of a 4,6-di(aziridin-1-yl)-1,3,5-triazine–benzimidazole hybrid as a potential dual-targeting anticancer agent. Future Medicinal Chemistry. https://doi.org/10.1080/17568919.2026.2658014

Source records

crossref · retrieved 2026-09-26T18:21:57.962Z